OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.46 Million Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 27.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 172,693 shares of the specialty pharmaceutical company's stock after buying an additional 37,141 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.35% of KalVista Pharmaceuticals worth $1,463,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in KALV. Aquatic Capital Management LLC bought a new position in KalVista Pharmaceuticals during the fourth quarter worth about $44,000. Tower Research Capital LLC TRC lifted its stake in KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares during the period. Legal & General Group Plc lifted its stake in KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares during the period. Martin Worley Group bought a new position in KalVista Pharmaceuticals during the fourth quarter worth about $86,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after purchasing an additional 2,043 shares during the period.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV traded up $0.27 during trading on Friday, reaching $11.93. The stock had a trading volume of 413,615 shares, compared to its average volume of 420,266. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50. The business's 50-day moving average price is $12.02 and its 200 day moving average price is $10.42. The stock has a market capitalization of $593.11 million, a PE ratio of -3.28 and a beta of 0.05.

Analyst Ratings Changes

A number of research analysts have commented on KALV shares. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 price target for the company. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Jones Trading restated a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, KalVista Pharmaceuticals has an average rating of "Buy" and a consensus target price of $24.83.

Insider Activity

In related news, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the acquisition, the insider now directly owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. This trade represents a 0.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the sale, the chief executive officer now directly owns 287,811 shares of the company's stock, valued at approximately $3,445,097.67. This represents a 2.26% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,292 shares of company stock worth $184,625. Insiders own 10.50% of the company's stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).